tiprankstipranks
Trending News
More News >
Sangamo Biosciences (SGMO)
:SGMO
Advertisement

Sangamo Biosciences (SGMO) AI Stock Analysis

Compare
2,417 Followers

Top Page

SGMO

Sangamo Biosciences

(NASDAQ:SGMO)

Rating:47Neutral
Price Target:
$0.50
▼(-3.85% Downside)
Sangamo Biosciences' stock score is primarily impacted by its poor financial performance, characterized by declining revenue and profitability, and a weak balance sheet. While there are positive developments in clinical trials and strategic initiatives, these are overshadowed by financial instability and the need for additional funding. Technical indicators provide some neutral signals, but valuation metrics suggest the stock is overvalued.
Positive Factors
Clinical Trials
The registrational Phase 1/2 STAAR trial in Fabry disease has delivered positive top-line results across renal, cardiac, and quality-of-life endpoints.
Partnerships
The proprietary STAC-BBB capsid has now attracted three blue-chip pharma partnerships, generating $88 million in upfront payments with more than $4.6 billion in potential milestones.
Regulatory Pathway
SGMO announced alignment with FDA on a regulatory pathway to accelerated filing for their AAV-based GTx '920 for Fabry disease.
Negative Factors
Financial Performance
SGMO reported a net loss of ~$20M.
Risks
Risks include clinical development risk tied to isa-vec, commercialization risk, and reimbursement risk among others.

Sangamo Biosciences (SGMO) vs. SPDR S&P 500 ETF (SPY)

Sangamo Biosciences Business Overview & Revenue Model

Company DescriptionSangamo Biosciences, Inc. (SGMO) is a clinical-stage biotechnology company focused on developing innovative genetic therapies to treat severe diseases. The company leverages its proprietary gene editing platform, which includes zinc finger protein (ZFP) technology, to create targeted therapies for genetic disorders, hemophilia, and other diseases. Sangamo operates primarily in the fields of gene therapy, gene regulation, and cell therapy, and is committed to advancing its pipeline of product candidates through clinical trials and partnerships.
How the Company Makes MoneySangamo generates revenue through a combination of collaborations, licensing agreements, and funding from governmental grants and private investments. Key revenue streams include milestone payments and royalties from partnerships with major pharmaceutical companies, such as Pfizer and Biogen, in which Sangamo provides its gene editing technology for the development of novel therapies. Additionally, the company may receive upfront payments in collaboration agreements, as well as potential future earnings tied to the successful commercialization of partnered products. Sangamo also engages in research grants and funding opportunities to support its R&D efforts, further contributing to its overall revenue.

Sangamo Biosciences Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in advancing their clinical and preclinical pipeline, particularly with positive results in the STAAR study for Fabry disease and progress in neurology and prion disease programs. Despite these advancements, challenges remain, including the need to secure additional funding and a Fabry commercialization partner. The sentiment is generally positive but tempered by financial uncertainties.
Q2-2025 Updates
Positive Updates
Positive Results from STAAR Study in Fabry Disease
The registrational Phase 1/2 STAAR study showed positive top-line results with a mean annualized eGFR slope of almost 2 at 52 weeks across 32 patients. The FDA agreed that this metric will serve as the primary basis of approval under the accelerated approval pathway.
Neurology Genomic Medicine Company Milestone
Sangamo initiated its first clinical site in the Phase 1/2 STAND study in chronic neuropathic pain, marking its transition to a clinical stage neurology genomic medicine company.
Prion Disease Program Advances
A productive meeting with the U.K.'s MHRA was held for the preclinical prion disease program, with a planned CTA submission as early as mid-2026.
Equity Offering Completed
Sangamo completed an equity offering expected to fund planned operations into the fourth quarter of 2025, bridging to an anticipated Fabry commercialization agreement.
Negative Updates
Fabry Disease Patient Resumes ERT
Following the top-line readout, one patient resumed enzyme replacement therapy (ERT) despite stable lyso-Gb3 levels and maintained supraphysiological levels of alpha-Gal A activity.
Need for Additional Funding
Sangamo's operations are contingent on securing additional funding and a Fabry commercialization partner, highlighting financial challenges.
Company Guidance
During the Sangamo Therapeutics Second Quarter 2025 Teleconference Call, the company provided guidance on several key metrics and milestones. Sangamo announced positive top-line results from the STAAR study for Fabry disease, highlighting a positive mean annualized eGFR slope of almost 2 at 52 weeks across all 32 dosed patients, with the FDA agreeing that this will serve as the primary basis for accelerated approval. Additionally, a positive eGFR slope of 1.7 was observed in 19 patients after two years. The company also initiated its first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain, expecting to dose the first patient in the fall of 2025 and have preliminary efficacy data by the fourth quarter of 2026. Furthermore, Sangamo is on track for a planned CTA submission for its prion disease program by mid-2026. Financially, the company completed an equity offering and expects its current cash runway to fund operations into the fourth quarter of 2025, while actively seeking a Fabry commercialization partner.

Sangamo Biosciences Financial Statement Overview

Summary
Sangamo Biosciences is facing significant financial challenges, including declining revenue, negative profitability, a weakening balance sheet with increased leverage, and persistent negative cash flows. These factors indicate financial instability and increased operational risks.
Income Statement
35
Negative
Sangamo Biosciences has shown significant volatility in its revenue and profitability metrics. There has been a substantial decline in total revenue from $176.23M in 2023 to $57.8M in 2024, representing a negative revenue growth trend. Gross profit margins have been inconsistent, and the company consistently reports negative EBIT and net income margins, indicating ongoing operational and profitability challenges.
Balance Sheet
40
Negative
The balance sheet reflects a strained financial position with a declining equity base, from $82.89M in 2023 to $22.77M in 2024. The debt-to-equity ratio has worsened due to reduced equity, suggesting increased leverage. The equity ratio declined significantly, indicating reduced shareholder equity relative to total assets, potentially increasing financial risk.
Cash Flow
30
Negative
The cash flow statements highlight persistent negative free cash flow, with a slight improvement from -$246M in 2023 to -$67.4M in 2024. Operating cash flow has remained negative, raising concerns about the company's ability to generate cash from operations. The free cash flow to net income ratio remains unfavorable, reflecting poor cash conversion.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue81.71M57.80M176.23M111.30M110.70M118.19M
Gross Profit79.58M57.80M154.04M99.19M101.26M-62.45M
EBITDA-56.86M-89.09M-240.71M-189.17M-173.90M-123.87M
Net Income-63.31M-97.94M-257.83M-192.28M-178.30M-121.12M
Balance Sheet
Total Assets97.56M101.64M165.32M562.51M721.92M938.55M
Cash, Cash Equivalents and Short-Term Investments38.34M41.92M81.00M277.63M376.55M641.42M
Total Debt23.46M30.57M38.10M43.11M48.08M42.09M
Total Liabilities77.96M78.86M82.43M267.55M346.58M441.18M
Stockholders Equity19.60M22.77M82.89M294.96M375.34M497.37M
Cash Flow
Free Cash Flow-36.19M-67.41M-246.00M-243.80M-256.53M155.16M
Operating Cash Flow-35.90M-67.14M-224.84M-223.63M-233.25M169.88M
Investing Cash Flow1.53M37.52M153.53M59.28M248.20M-271.63M
Financing Cash Flow43.54M28.38M14.59M84.66M32.86M153.10M

Sangamo Biosciences Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.52
Price Trends
50DMA
0.53
Negative
100DMA
0.56
Negative
200DMA
1.00
Negative
Market Momentum
MACD
<0.01
Positive
RSI
46.49
Neutral
STOCH
9.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMO, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.53, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 46.49 is Neutral, neither overbought nor oversold. The STOCH value of 9.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SGMO.

Sangamo Biosciences Risk Analysis

Sangamo Biosciences disclosed 57 risk factors in its most recent earnings report. Sangamo Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sangamo Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$287.69M-38.87%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
47
Neutral
$156.89M-298.41%565.52%79.44%
46
Neutral
$134.13M-97.49%-100.00%62.82%
45
Neutral
$609.08M-35.02%20.37%
38
Underperform
$226.37M-66.75%-5.57%
30
Underperform
$172.04M-9999.00%-4.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SGMO
Sangamo Biosciences
0.52
-0.29
-35.80%
ANNX
Annexon Biosciences
2.06
-3.35
-61.92%
IKT
Inhibikase Therapeutics
1.80
0.46
34.33%
FDMT
4D Molecular Therapeutics
6.16
-8.58
-58.21%
ELTX
Elicio Therapeutics
10.53
6.66
172.09%
TERN
Terns Pharmaceuticals
6.96
-0.27
-3.73%

Sangamo Biosciences Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Sangamo Announces Positive Results for Fabry Disease Therapy
Positive
Jun 24, 2025

On June 24, 2025, Sangamo Therapeutics, Inc. announced positive topline results from its Phase 1/2 STAAR study of isaralgagene civaparvovec, a gene therapy for Fabry disease. The study showed significant improvements in kidney function and quality of life measures, with a favorable safety profile. These results support the potential of isaralgagene civaparvovec as a one-time treatment for Fabry disease, paving the way for a Biologics Licensing Application under the Accelerated Approval pathway by early 2026.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Sangamo Biosciences Approves Amendments to Equity Plan
Positive
Jun 16, 2025

On June 12, 2025, Sangamo Therapeutics, Inc. held its annual meeting where stockholders approved significant amendments to the 2018 Equity Incentive Plan. This included increasing the number of shares available for issuance and the number of shares for incentive stock options. The meeting also saw the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the company’s independent auditor. These decisions reflect Sangamo’s strategic focus on expanding its equity incentives to attract and retain talent, which could enhance its competitive position in the biotech industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 26, 2025